Click the 'X' in the top right corner to close this window.
Thought Leadership
MoneyTreeTM: A case for cautious optimism
Life sciences venture capital (VC) investment recovered in terms of dollar investments during the first quarter of 2011 with $1.4b going to 164 deals, according to the PwC/NVCA MoneyTree Report with data from Thomson Reuters. Quarterly venture investment grew 7 percent year over year and 16 percent from the previous quarter. However deal volume did decline by 8 percent compared to the same period last year.
The top five metropolitan regions receiving life sciences venture capital funding during Q1 2011 were San Francisco Bay ($381 million), New York Metro ($190 million), Boston ($182 million), San Diego Metro ($82 million), and North Carolina Research Triangle ($68 million). Investments in biotechnology deals accounted for 76 percent of the dollars invested in the top five regions in Q1 2011.
The top five metropolitan regions receiving life sciences venture capital funding during Q1 2011 were San Francisco Bay ($381 million), New York Metro ($190 million), Boston ($182 million), San Diego Metro ($82 million), and North Carolina Research Triangle ($68 million). Investments in biotechnology deals accounted for 76 percent of the dollars invested in the top five regions in Q1 2011.
Look for papers, articles, and case studies. See all thought leadership.
Contacts
- Mike Galper
- US healthcare payer leader
- Tel: +1 (213) 217 3301
- Robert Valletta
- US healthcare provider leader
- Tel: +1 (617) 530 4053
- Michael Swanick
- Global Leader Pharmaceuticals & life sciences
- Tel: +1 (267) 330 6060
